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BIOTECHNOLOGY OF ENDOPHYTIC FUNGI: INORGANIC
NANOMATERIALS AND DRUGS
Absar Ahmad
Biochemical Sciences Division, National Chemical Laboratory, Pune 411008, MS, India.
e-mail: a.ahmad@ncl.res.in
One of the important challenges of considerable topical significance in nanotechnology is the
development of eco-friendly experimental processes for the economical synthesis of nanomaterials in
large quantities of variable size, shape, and chemical composition. While it is recognized that some of the
most exquisite nanomaterials are made by biological systems (examples include silica in diatoms and
magnetite in magnetotactic bacteria), the potential to exploit microorganisms in a creative manner in the
laboratory for eco-friendly synthesis of nanomaterials is still largely under-exploited.
In this presentation, we describe our research into the use of plant microorganisms and plant extracts in
the synthesis of metal, metal sulfide, and oxide nanoparticles. In a significant departure from bacteria-based
methods for nanomaterial synthesis that have been investigated in some detail, we have shown that plant
microorganisms such as fungi and actinomycetes when challenged with aqueous metal ions are capable of
reducing the ions both intra- and extracellularly resulting in the formation of stable metal nanoparticles. The
formation of metal nanoparticles occurs by an enzymatic process and thus, the fungus-based synthesis
process is not limited to reduction reactions alone. The versatility of this approach is underlined by our
findings that enzymes such as sulphite reductase, nitrate reductase, and hydrolyzing proteins are secreted by
the fungi in response to metal stress thereby leading to the possibility of synthesis of quantum dots, metal
nanoparticles, and nanooxides. The biosynthesis of nanooxides using fungi is exciting since the synthesis
occurs at room temperature and thus could be of considerable commercial value.
Fungi enjoy a close symbiotic relationship with plants and hence, it is quite likely that plant extracts
may also possess useful biomolecules that not only carry out the range of biotransformations listed above,
but also control the shape of nanoparticles. We have studied a number of plant extracts for realizing metal
nanoparticles and have observed that the Geranium and Lemongrass extracts result in shape modulated
gold nanoparticles. In particular, the reaction of aqueous gold ions with Lemongrass extract resulted in
the large-scale synthesis of gold nanotriangles with interesting near infrared absorption. Potential
application of the gold nanotriangles and magnetite nanoparticles in hyperthermia of cancer cells and
targeted drug delivery are being investigated.
We have also isolated, purified, and completely characterized a range of plant-based drugs such as
Taxol, Vinblastine, Vincristine, Artemisinin, and Phyllanthin from endophytic fungi and recently initiated
further important steps of functionalizing the nanoparticles synthesized by green chemistry approach for
drug delivery application.





UTILIZATION OF 1,3-DIPOLAR CYCLOADDITION REACTION OF
AZIDES TOWARD THE SYNTHESIS OF 5-MEMBERED HETEOCYCLIC
COMPOUNDS
Sultan T. Abu-Orabi
President, Yarmouk University, Irbid, Jordan. e-mail: abuorabi@excite.com; president@yu.edu.jo
1,3-Dipolar cycloaddition of organic azides to acetylenic and ethylenic compounds is the most important
method for the synthesis of 1,2,3-triazole and triazoline derivatives, respectively. We have found that the
reaction of substituted benzyl azides 1 and bis-(azidomethyl) benzenes 2 with dibenzoylacetylene 3 followed






































We also synthesized a series of 4,5-bis[5-aryl-1,3,4-oxadiazol-2-yl]-1-substituted benzyl-1,2,3-
triazoles 8 upon dehydration of 4,5-bis [N-aroyl-N-hydrazinocarbonyl]-1-substituted benzyl-1,2,3-
triazoles 7 (generated from substituted benzyl azides, dimethyl acetylenedicarboxylate, and hydrazine).
In a similar way, we prepared a series of 2-[1-benzyl-1,2,3-triazolo-4]-5-aryl-1,3,4-oxadiazoles 11 via















































































R= -Cl, Br, F, CH 3, OCH3, NO2, Pentamethyl
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CLASSICAL AND NOVEL BIOLOGICS TARGETING CHRONIC
INFLAMMATION
Ian Ahnfelt-Rønne
Novo Nordisk A/S, Biopharmaceuticals Research Unit, 2760 Maalov, Denmark.
e-mail: iar@novonordisk.com
The therapeutic potential of the classical biologics targeting chronic inflammation is based on their ability
to block the function of TNF-a, which is considered the master regulator of inflammatory responses in
many organ systems. This class of compounds includes etanercept (Enbrel), an Fc fusion protein of TNF-
a receptor 2 that was first introduced in 1998; infliximab (Remicade), a chimeric IgG antibody against
TNF-a, launched for Crohn’s disease in 1998 and rheumatoid arthritis (RA) in 1999; and adalimumab
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(Humira), a human anti-TNF-a antibody for RA and other chronic inflammatory conditions such as
psoriasis and ankylosing spondylitis (2003). Other recently introduced anti-TNF-a biologics are Cimzia
and Golimumab. This class of biologics is, with a few exceptions, broadly efficacious in treating a variety
of autoimmune disorders such as RA and related arthritic conditions, Crohn’s, and psoriasis. However,
significant numbers of patients do not, or do only partially respond to treatment, and in others the effect
wanes over time. Hence, novel biologics targeting alternative key regulators of the immune response have
been introduced, and even more are in clinical and preclinical development. New targets include
leukocyte surface proteins, complement, B lymphocytes, adhesion molecules, interferons, and a plethora
of interleukins. The receptor of complement fragment C5a, C5aR, has been shown to be an important
mediator of inflammatory arthritis in mice, in as much as a human antibody against C5aR was highly
effective in reversing arthritis in a mouse model where the murine C5aR gene had been replaced with the
human version.1 The IL-10 subfamily members, IL-20 and IL-24, and their receptors were expressed in
synovium of RA and spondyloarthropathy pointing to an association with pathology in these conditions.2
Based on these observations, anti-C5aR and anti-IL-20 antibodies have entered into clinical development
targeting chronic inflammation.
1. Lee et al., Nat. Biotechnol., 2006, 24, 1279.
2. Kragstrup et al., Cytokine, 2008, 41, 16; 1995, 34, 91.
DNA-TOPOISOMERASE INHIBITORY ACTIVITY OF SOME
HETEROCYCLIC COMPOUNDS AND THEIR
STRUCTURE–ACTIVITY RELATIONSHIPS
Esin Aki, Ismail Yalcin, Ilkay Yildiz, Ozlem Temiz-Arpaci, Kayhan Bolelli, Tugba Ertan-Bolelli
Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ankara University, Tandogan 06100
Ankara, Turkey. e-mail: esinaki@ankara.edu.tr
Eukaryotic topoisomerases is widely used in anticancer drug development that they are essential for
several cellular processes such as replication, transcription, and chromosome condensation. Their
antitumor activity is related to the formation of protein-concealed DNA strand breaks, resulting in the
stabilization by the drug of an intermediary complex of the Topo II reaction.1
In this study, a new series of benzazoles, has been investigated for their inhibitory activity on
eukaryotic DNA topoisomerase II in cell free system.2 The goal of this research was that predictions from
the structure activity relationships of these tested compounds possibly will lead to design more active new
DNA topoisomerase II inhibitors.
For the structure–activity relationship studies pharmacophore analysis was performed using Catalyst
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NATURAL PRODUCT-INSPIRED SMALL MOLECULES AS
MODULATORS OF CELL DEATH PATHWAYS INVOLVING BCL-2
Family
Prabhat Arya
Chemical Biology Program, Institute of Life Sciences (An Associate Institute of University of Hyderabad),
University of Hyderabad Campus, Gachibowli, Hyderabad 500046, India; Adjunct Professor,
Biochemistry, McGill University; Affiliate Investigator, Ottawa Hospital Research Institute; Member,
Ottawa Institute of Systems Biology. e-mail: prabhata@ilsresearch.org,
web: http://www.ilsresearch.org (see: chemical biology)
The research in our group aims at developing methods leading to high-throughput generation of natural
product-inspired compounds with the goals of identifying chemical modulators of protein–protein
interaction-based signaling pathways. Over the years, although the high-throughput synthetic approaches
have been very successful in generating a large number of small molecules but in most cases, these
compounds are simple in nature and thus lack the features that are commonly found in bioactive natural
products (i.e., 3D architectures, rich in chiral display of dense functional groups, etc.). Through working
in collaboration with David Andrews Team at McMaster University, several novel functional, chemical
probes have been identified to date as chemical modulators of Bcl-2 protein family. The assays developed
in his group are highly unique and allow us to investigate the modulation of protein–protein interactions
and their functions in a membrane environment.
This talk will focus on the need to access novel natural product-inspired architectures in the post-
genomic drug discovery arena.
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CADD AND SYNTHESIS IN THE DESIGN OF ANTI-MALARIAL AGENTS
Prasad V. Bharatam
Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research
(NIPER), S.A.S. Nagar, Mohali 160 062, Punjab, India. e-mail: pvbharatam@niper.ac.in
A new class of chemical species with the general formula N(/L)2 (I), with a formal N(+1) oxidation
state has been identified.1 Several known molecules belong to this hitherto unrecognized class—well
known example is the anti-malarial prodrug proguanil hydrochloride. Electronic structure analysis
indicates that this class of compounds possesses two lone pairs of electrons on a nitrogen atom with a
formal positive charge. The central core of this class of molecules is isoelectronic to the central core of
carbodicarbenes C(/NHC)2 (II), thus, offers ample opportunities for basic and applied research in
chemistry. This electronic environment in biguanide analogs, offers increased dynamism to the system
through reduced C=N rotational barriers and easy N-inversion processes. Several clues have been
obtained from the above analysis, which helped in the design and synthesis of anti-malarial guanyl
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thiourea derivatives (IV). QSAR, Pharmacophore mapping, molecular docking, and virtual screening
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A PRACTICAL APPROACH FOR DEVELOPING NEXT GENERATION
SAFE AND EFFECTIVE DRUGS
Laxminarayan Bhat
Reviva Pharmaceuticals, Inc. 5941 Optical Court, San Jose, CA 95138, USA.
e-mail: LBhat@Revivapharma.com
Drug discovery and development is a complex and highly challenging process. Despite significant
advances in biomedical research over the last three to four decades, the attrition rates of new chemical
entities (NCEs) in preclinical and clinical development are staggeringly high.1 In addition, several
approved drugs have been withdrawn from the market in recent years due to their serious adverse drug
reactions2,3 (ADRs) leading to number of reported deaths. Therefore, in addition to finding the right
strategy and target the ability to assess the efficacy and safety profile of NCEs early in the development
process holds tremendous value for the pharmaceutical industry.
Reviva Pharmaceuticals, Inc., is focused on developing novel Redesigner DrugsTM for CNS,
metabolic, cardiovascular, and inflammatory indications by redesigning the approved existing drugs
which are known to cause ADRs. Reviva’s innovative drug development approach has several advantages
over the conventional de novo approach such as the ability to assess the efficacy and safety profile of
NCEs throughout the development process, reduced cost and time to market. The company believes that
the redesigned drugs will be safe and efficacious than the existing drugs. Reviva’s drug development
approach including the preclinical efficacy and safety profiles of the redesigned drugs for obesity
(RP1000) and schizophrenia/bipolar (RP5000) indications will be presented.
References
1. Shah, S., Drug Discov. Today 2009, 14, 1006.
2. Goldstein, D. B., N. Engl. J. Med. 2003, 348, 553.
3. Weinshillboum, R., N. Engl. J. Med. 2003, 348, 529.
S8 Med Chem Res (2010) 19:S3–S41
COPPER-CATALYZED REACTIONS FOR THE SYNTHESIS OF
BIOLOGICALLY ACTIVE HETEROCYCLES
Uwe Beifuss
Bioorganic Chemistry, Department of Chemistry, University of Hohenheim, Garbenstr. 30,
70599 Stuttgart, Germany. Fax: +49-711-45922951; email: ubeifuss@uni-hohenheim.de
In the light of the growing importance of enzymatically catalyzed reactions, it is surprising that the
potential of enzymatically initiated domino reactions has so far hardly been exploited. In this context,
enzymes that are capable of conducting an oxidation triggering a domino reaction are very promising.
This is why laccases have a very high potential for the development of oxidative domino processes.
Laccases (E.C. 1.10.3.2) are multicopper oxidases that are capable of oxidizing a wide range of substrates
while concomitantly reducing O2. They contain a T1, a T2, and a T3 Cu center. T2 and T3 form a
trinuclear Cu cluster. The oxidation of the substrate occurs at the T1 Cu center. The electrons are













Here we report on the efficient laccase initiated domino reactions of a multitude of 1,3-dicarbonyls
with catechols into heterocycles with a benzofuran core employing air as an oxidant.1-3 We also
highlight on the combined action of a tyrosinase and a laccase which allows the use of phenol instead of



















HH cat. laccase, O2
(-)-pinoresinol(+)-pinoresinol
AtDIR6
We also present the cloning, expression, purification, and functional characterization of a dirigent
protein (AtDIR6) from Arabidopsis thaliana, which mediates the laccase-catalyzed enantioselective
oxidative phenol coupling of coniferyl alcohol to (-)-pinoresinol.5 We further show that the
enantioselectivity of AtDIR6 is opposed to that of the known dirigent protein FiDIR1 from Forsythia.
A third project addresses the use of Cu(I)-catalyzed sequential processes for the synthesis of
heterocycles which is exemplified by the reaction of 2-bromobenzyl bromide with b-ketoesters to yield
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THE FIGHT AGAINST AIDS: THE ‘‘OLD’’ REVERSE TRANSCRIPTASE
(RT) AND THE ‘‘NEW’’ DDX3
Maurizio Botta
Dipartimento Farmaco Chimico Tecnologico, University of Siena, Via Aldo Moro, 53100 Siena, Italy.
e-mail: botta@unisi.it
A multitarget approach to fight the HIV-1 virus is presented. It is focused on the inhibition of HIV-1
reverse transcriptase (RT) and of DDX3, a DEAD box ATP-dependent RNA helicase. RT is a
multifunctional enzyme, consisting of a p66 and a p51 subunits, responsible for the conversion of the
single-stranded RNA viral genome into a double-stranded DNA. Lacking a biological counterpart in the
eukaryotic systems, RT is an attractive target for development of selective inhibitors. Among non-
nucleoside RT inhibitors (NNRTI), dihydro-alkoxy-benzyl-oxopyrimidines (DABOs) are an interesting
class of compounds active at nanomolar concentration, that were first discovered in 1992 and further
developed during the following years into S-DABO and related analogues. Several innovative molecular
modeling and synthetic techniques were successfully applied to improve the activity of a class S-DABOs
toward wt RT and some clinically relevant mutants and to the identification of the first RT dimerization
inhibitor. Furthermore, a combinatorial approach led to the identification of a new class of compounds
(namely 6-vinylpyrimidines) endowed with an unprecedented mechanism of action. These compounds are
the first NNRTIs competing with the nucleotide substrate. An enzymological and computational study,
followed by the crystallization of the complex between RT and a 6-vinylpyrimidine, has been conducted
to elucidate their unique mechanism of action.1-3
Compounds currently used for the treatment of HIV-1 infections are targeted to viral proteins.
However, the high intrinsic mutation and replication rates of HIV-1 led to the emergence of drug-resistant
strains with a consequent therapeutic failure. On this basis, cellular cofactors represent attractive new
targets for HIV-1 chemotherapy, since targeting a cellular factor that is required for viral replication
should help to overcome the problem of viral resistance. In this context, a structure-based
pharmacophoric model based on the X-ray crystallographic structure of human helicase DDX3 was
inserted in a virtual screening approach leading to the discovery of the first small molecule inhibiting
HIV-1 replication by targeting DDX3. It represents a hit compound for a completely new class of antiviral
agents.4
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NOVEL QUANTITATIVE STRUCTURE–ACTIVITY ANALYSES OF
PROTEIN INHIBITORS USING FULL AB INITIO MOLECULAR
ORBITAL CALCULATIONS ON THEIR COMPLEX STRUCTURES WITH
PROTEIN
Tatsusada Yoshida, Yohei Munei, Hiroshi Chuman
Institute of Health Biosciences, University of Tokushima, 1-78, Shomachi, Tokushima, 770-8505, Japan.
e-mail: hchuman@ph.tokushima-u.ac.jp
A novel QSAR procedure has been desired to understand quantitatively the ligand–protein interaction at
atomic and electronic levels. In this paper, we demonstrate the performance of our recently proposed
novel QSAR procedure using ab initio fragment molecular orbital (FMO) calculations on ligand–protein
complex structures.1,2
1. Cyclic urea type inhibitors (CUIs) of HIV-1 protease (HIV-1 PR)
QSAR analyses on a series of CUIs including DMP323 were performed using molecular dynamics (MD)
and FMO (HF/6-31G and MP2/6-31G) calculations on the whole complex structure of HIV-1 PR with
each CUI. Two descriptors showing correlation with the inhibitory potency (log (1/Ki)) were the total
electronic interaction energy and the change in the accessible surface area (DASA) on the complex
formation. The Inter-Fragment Interaction Energy (IFIE) term is one of the most advantageous outcomes
directly obtained from the FMO theory. Figure 1 shows IFIE values of DMP323 with all the amino acid
residue fragments (99 9 2) in HIV-1 PR. The IFIE analysis revealed that the major contribution to the
variations in the total electronic interaction energy comes from amino acid residues surrounding a CUI,
especially from Asp30. The inhibitory potency is nicely expressed using DASA and [IFIE(30) + I-
FIE(31)], which represents the electronic interaction energy of Asp30 (300) with a CUI.
log (1/Ki) = -0.0306 [IFIE(30) + IFIE(31)] + 9.55 9 10
-3 DASA + 19.1
n = 13, r = 0.910, s = 0.485, F = 24.2 (MP2/6-31G)
2. Benzenesulfonamides (BSAs) with carbonic anhydrase (CA)
QSAR analyses on the binding potency (log Kb) of substituted BSAs with bovine CA were performed
according to the procedure similar to that used in 1. The modified IFIE analysis quantitatively revealed

































Fig. 1 IFIE map of CUI (DMP323) with HIV-1 PR
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Log Kb = -0.245Rin the active site IFIE (i) - 23.9.
n = 16, r = 0.983, s = 0.211, F = 392 (HF/6-31G); n = 16, r = 0.983, s = 0.211, F = 392 (HF/6-
31G).
Zn block (Zn2+, His93, His95, and His118) gives the lowest interaction energy and the largest variance of
interaction energy with CA through their coordination interaction, and govern the binding potency
dominantly.
The two examples are reasonably considered to show that the novel descriptors obtained from the
MD-FMO procedure are able to represent physicochemical features of the ligand–protein interaction
clearly. It is noteworthy that the IFIE term attributable to the interaction energy of a ligand with a
component amino acid residue in the protein, instead of the classical QSAR parameters attributable to a
ligand, is able to work as QSAR descriptors in analyzing the complex formation. The results also provide
an answer as to why the classical QSAR descriptors such as Hammett r are frequently significant in the
enzymatic QSAR equations.
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PYRROLO-QUINOLINONES WITH POTENT
PHOTOCHEMIOTHERAPEUTIC ACTIVITY WITHOUT DNA DAMAGE
Girolamo Cirrincione
University of Palermo, Dipartimento Farmacochimico Tossicologico e Biologico, Via Archirafi 32,
90123 Palermo, Italy. e-mail: gcirrinc@unipa.it
PUVA therapy combines the use of Psoralen 1 with UVA radiation for the treatment of dermatological































Fig. 2 BSA bound in the active
site of CA











X-X= CH2-CH2 or CH=CH
H
3 Y=C-R, W=N-R, Q=C-Me
4 Y=W=C-R, Q=N-R
5 Y=N-R, Q=C-R, W=C-H
The introduction of extracorporeal photochemotherapy2 (ECP) represents an evolution of the PUVA
therapy for the treatment of cutaneous T-cell lymphoma (CTCL), T-cell mediated autoimmune diseases.3
Unfortunately, the antiproliferative effect of this class of linear furocoumarins, is associated to
undesiderable short- and long-term side effects. These latter, such as genotoxicity and mutagenicity, are
caused by interstrand crosslinks (ISC).4 Angelicin 2, is an angular furocoumarin which, for its molecular
geometry, cannot produce ISC resulting less toxic than its linear congener. In this context several
angelicin isosters have been studied.5 We have recently reported the synthesis of pyrroloquinolinones of
type 3–5 to verify the influence of the condensation of the pyrrole ring to the quinoline moiety. Such ring
systems showed potent photoantiproliferative activity being in some cases higher than 8-MOP (GI50 0.4–
16.4 lM, 0.4–15.0 lM, and 0.5–9.0 lM, respectively).6 Experiments performed to better understand the
biological targets, demonstrated that compound 3–5 do not interact with DNA, but mithocondria and
lysosomes may be involved in the photoinduced apoptotic cell death. The most relevant feature is that
pyrrolo[3,2-h]quinolinones 5 exhert their activity without inducing DNA photodamage.
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BIOACTIVE NATURAL PRODUCTS: NATURE’S GIFT TO SCIENCE
David Yu-Kai Chen
Chemical Synthesis Laboratory (CSL) @ Biopolis, Institute of Chemical and Engineering Sciences
(ICES), Agency for Science, Technology and Research (A*Star), 11 Biopolis Way, The Helios Block #03-
08, Singapore 138667, Singapore. e-mail: david_chen@ices.a-star.edu.sg
The total synthesis of natural products has served admirably as the cradle for the evolution of chemical
sciences, and nurtured the discovery of novel synthetic technologies and strategies. In conjunction with
the biological activities harnessed by the natural substances, accessing natural and designed compounds
by chemical means also has a cemented position in bridging biology and medicine. Chemical Synthesis
Laboratory @ Biopolis has been actively pursuing number of architecturally complex natural products
exhibiting promising therapeutic potentials, and served a crucial role in advancing our understanding in
chemistry and chemical biology. In this talk, recently accomplished total syntheses of bioactive natural
products will be described. Emphasis will be placed on the strategic design and recognizing the unique
reactivity embedded within the molecular scaffold, and opportunities in the application of synthetic
technologies in chemical-biology investigations.
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AChE INHIBITORSELECTIVE CYTOTOXIC AGENT
H
H
R = H: ECHINOPINE A
R = Me: ECHINOPINE B
CO2R
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TOWARDS ACCELERATED ANTI-CANCER DRUG DISCOVERY:
INTEGRATION OF CHEMOINFORMATICS, CELL-BASED SCREENING,
AND GRID COMPUTING
Gyo¨rgy Dorma´n,1 Sa´ndor Cseh,1 Istva´n Ba´gyi,1 Pe´ter Kacsuk,2 Jo´zsef Kova´cs,2 Angelo Carotti,6
Orazio Nicolotti,6 Simona Distinto,3 Gerhard Volber,3 Amiram Goldblum,4 David Marcus,4
Alfons Nonell-Canals,5 Jordi Mestres,5 Andre Lomaka,7 Miklo´s J. Szabo´,8 Be´la Berto´k8
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Victor Hugo u. 18-22, Budapest, 1132, Hungary; 3Inte:Ligand GmbH, Clemens Maria Hofbauer-Gasse 6,
2344 Maria Enzersdorf, Austria; 4Hebrew University of Jerusalem, Jerusalem 91120, Israel; 5University
Pompeu Fabra; Barcelona Biomedical Research Park C/Doctor Aiguader, 88, 08003 Barcelona, Spain;
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CancerGrid, a 3-year European Research Project (www.cancergrid.eu) aims to integrate computer
technologies, chemistry and biology to facilitate the discovery of potential anti-cancer agents. The core of
this approach is comparative cell-based screening (applying cancer and reference cell lines), which not
only validates the hits (selectively cytotoxic compounds) as potential anti-cancer agents, but also fits to
the latest concept of polypharmacology. In the first phase of the project, 30,520 small molecules were
selected by various state-of-the-art computational methods from the AMRI library of 200,000 compounds
and University of Bari internal collection of 1,500 compounds. Single point high-throughput screening of
the selected compounds was performed on HCT116 colon cancer cells at 50 lM concentration. From the
resulting cytotoxic compounds (\20% viability), a diverse sublibrary was selected for IC50 determination
on HCT116 and on the reference MRC-5 cell-line. In the next phase, a QSAR model was attempted to
build based on the screening results for predicting disease-related cytotoxicity utilizing a purpose-built
grid computing system. Iterative stochastic elimination (ISE) indexing method was extended to calculate
a Cyto-Toxicity Index (CTI) from the hit compounds, which can prioritize potential cytotoxic compounds
in large databases. Since it is assumed that related chemical structures act through similar targets and
signaling pathways, the model building was supported with an in silico target annotation method. The
final stage of the project is in silico design of anti-cancer focused libraries and its experimental validation.
In the lecture, the CancerGrid system will be described together with the results and the experience
gained during the development of the grid infrastructure and the project execution.
FROM 2D TO 4D QSAR MODELING: MODEL BUILDING AND
VALIDATION ON HIV-INTEGRASE INHIBITORS
Ma´rcia M. C. Ferreira
Institute of Chemistry, University of Campinas, 13083-740 Campinas, SP, Brazil.
e-mail: marcia@iqm.unicamp.br
Quantitative structure–activity relationships (QSARs) is now-a-days a very heterogeneous area of
theoretical medicinal chemistry, mainly because of several ways to calculate, use and interpret molecular
descriptors: ranging from so-called 2D or classical, over 3D, 4D, and higher dimensional, to hybrid (2D/
3D, 2D/4D etc.) QSARs. Our group has experience with a variety of 2D, 3D, and 4D QSARs, resulting in
a recently launched LQTA-QSAR,1 a free, 4D-QSAR software. It is based on GROMACS molecular
simulations, use of conformational ensemble profile for each compound coupled with the calculation of
the 3D descriptors for diverse probes (LQTAgrid module). QSAR Modeling is the other free, home-made
software, designed for chemometrically correct model building using PLS, and validation independently
on the type of QSAR descriptors used. It takes into account basic statistical issues that are frequently not
well or completely carried out in QSAR publications: transparent and effective variable pre-selection and
selection with the Ordered Predictors Selection (OPS) algorithm2 also recently published by our group;
outlier detection; leave-many-out crossvalidation; Y-randomization; multicollinearity (especially the sign
change problem) and consistent model interpretation. This lecture will illustrate all these aspects for 2D,
3D, 4D, and mixed QSAR models for b-diketone inhibitors of the HIV-1 integrase, and discuss
advantages and disadvantages of particular models.
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RATIONAL DESIGN AND DEVELOPMENT OF A BROAD SPECTRUM
ANTIVIRAL DRUG: AN INTERFERON MIMETIC
Eleanor N. Fish, Lakshmi P. Kotra
Toronto General Research Inst., University Health Network & University of Toronto, 67 College Street,
Rm. 424, Toronto, Ontario M5G 2M1, Canada. e-mail: en.fish@utoronto.ca
IFNs-a/b function as the first line of defense against viral infections by modulating cell growth,
establishing an antiviral state and influencing the activation of various immune cells. In recent years,
emerging viral infections have become more frequent, creating an urgent need for effective therapeutic
solutions. Although vaccination against a specific virus is the best preventative approach, the time to
develop a targeted vaccine precludes its immediate use during an outbreak of a newly emerging virus.
Antiviral drugs can be deployed quickly and therefore represent the first line of defense during an initial
outbreak. Antiviral drug development to date has focused on each drug targeting a specific virus.
Antiviral drugs that are pathogen-specific have a role, yet concerns relating to the development of drug
resistance necessitates consideration of complementary antiviral strategies. An alternative strategy is to
focus on the host immune response to virus infection and identify specific factors that are rapidly
activated in response to many different virus infections. Interferons (IFN) are critical for host resistance to
viral infections, mediating direct antiviral responses in target cells, while inducing both innate and
adaptive immune responses in the infected host.
Hypothesis: Development of broad spectrum antivirals that are host-specific and not pathogen-specific
provides for widespread protection against emerging and re-emerging viruses and avoids drug resistance.
Approach: Enhance the host innate immune response by manipulating the IFN response. That is, develop
next generation IFN-as, IFN mimetics, as small molecule drugs.
Motivation: Historically, antiviral strategies involving vaccinations and antiviral have been pathogen
focused and some have serious downsides including increasing numbers of severe and drug-resistant
cases of disease, insufficient time to develop and manufacture targeted vaccines, limited quantities of
supplies, unpredictable efficacy.
Utilizing a model we have developed for the complex of IFN-a with the IFN receptor, IFNAR, comprised
of IFNAR1 and IFNAR2 subunits, we performed an in silico screen of the ZINC6 molecular database for
compounds that mimic IFN-a in the context of its interactions with IFNAR1 and IFNAR2. A set of 35
compounds with suitable characteristics were identified. Two compounds from the set of 35 were
selected, based on their chemical nature and their potential interaction with the receptor sites. Two
focused libraries of compounds, for a total of 50 compounds, are currently being evaluated for IFN
agonist bioactivity. Specifically, these compounds are evaluated for biopotency against a panel of viruses
in vitro and in vivo.
MODELING CHEMICAL REACTIONS IN DRUG DESIGN
AND CHEMICAL RISK ASSESSMENT
Johann Gasteiger
Computer-Chemie-Centrum, Universita¨t Erlangen-Nu¨rnberg, 91052 Erlangen, Germany; Molecular
Networks GmbH, Henkestr. 91, 91052 Erlangen, Germany. web: http://www.molecular-networks.com
Chemical reactions play a major role at many steps of the drug design process. A better understanding and
modelling of chemical reactions could greatly increase the efficiency in developing a new drug.
In target identification, an understanding of enzyme reactions is needed.
In lead discovery and lead optimization, an estimate of synthetic accessibility is desired, syntheses
have to be designed, and the synthesis of a library asks for knowledge on the scope and limitations of a
reaction type. Furthermore, knowledge on the stability of the compounds of a library is necessary.
The estimation of ADME-Tox properties has to model the metabolism of drugs and has to predict pKa
values. Furthermore, many toxic modes of action are the result of chemical reactions.
Legislature has been introduced in Europe (REACH—registration, evaluation and accreditation of
chemicals) that requires proof of the safety of chemicals that are in industrial use. As the testing of
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chemicals is time-consuming and expensive, computer methods for chemical risk assessment are being
developed in order to rank the chemicals for testing. This assessment of chemicals again asks for the
prediction of metabolism and of environmental degradation. Examples for modelling these various types
of chemical reactions will be given.1
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NOVEL THIAZOLYL THIAZOLYDIN-4-ONE DERIVATIVES AS HIV-1
REVERSE TRANSCRIPTASE INHIBITORS. POTENTIAL NOVEL DRUGS
FOR THE TREATMENT OF AIDS
Geronikaki Athina,1 Pitta Eleni,1 Surmava Sofiko,2 Eleftheriou Phaedra2
1Aristotle University if Thessaloniki, Greece; 2Alexandrion Technological Educational Institute of
Thessaloniki, Greece
Reverse transcriptase (RT) inhibitors are among the drugs mostly used for the treatment of human
immunodeficiency virus type 1 (HIV-1) infection. Although, many compounds are licensed and already
used as anti-HIV drugs, research on development of novel inhibitors continues since drug-resistant strains
appear inevitably because of prolonged therapy of the patients.
Both nucleoside/nucleotide (NRTI) and non-nucleoside analogues (NNRTI) have been used as RT-
inhibitors for decades with NNRTIs having the benefit of exhibiting less undesired side effects.
In the present study, thirteen N-{(MeO/EtO-benzo)[d]thiazolyl}-(2-(Cl/F-phenyl))-thiazolydin-4-one
derivatives were synthesised and tested as HIV-1 RT inhibitors.
Evaluation of their inhibitory action was made by a colorimetric photometric enzyme immunoassay
method.
According to the results, some of the tested compounds had IC50 values at the micromolar or
submicromolar range. Remarks on the effect of the kind and position of substituents were done.
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EXPLORING THE POTENTIAL OF BUCCAL DRUG DELIVERY FOR
ENHANCING DRUG THERAPY
Thirumala Govender
School of Pharmacy and Pharmacology, University of KwaZulu-Natal, Private Bag X54001 Durban,
4000, South Africa
Drug delivery via the buccal route has recently received increased interest in the literature as an
alternative to oral and other conventional routes of administration for the following reasons: preparations
administered via the buccal route are able to bypass enzymatic degradation and hepatic first pass
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metabolism thereby improving the systemic bioavailability of various drugs. Also, absorption following
administration via the buccal route is not influenced by potential variations in the gastric emptying rate or
the presence of food. This presentation will provide an overview of buccal drug delivery, approaches to
enhance drug permeability across the buccal mucosae and advantages and limitations of current drug
delivery systems being investigated. Examples of experimental studies currently being undertaken on
buccal drug delivery with antihypertensives and antiretrovirals at UKZN will be presented.
The group has been focusing on optimizing the design of films as a buccal drug delivery system and
examining the buccal permeability properties of various drugs. In a particular study, the aim was to
prepare and characterise monolayered multipolymeric films (MMFs) comprising of a hydrophilic drug
(Propranolol HCl) (PHCl), and polymers of opposing solubilities. Films were prepared by emulsification
and casted by a new approach using a silicone molded tray with individual wells. MMFs comprising of
PHCl with Eudragit 100 (EUD100) and Chitosan (CHT), i.e., films with drug and polymers of opposing
solubilities were successfully prepared (PHCl:EUD100:CHT; 1:10:0.5) and demonstrated uniform and
reproducible drug content (100.71 ± 2.66%), thickness (0.442 ± 0.030 mm), mucoadhesivity
(401.40 ± 30.73 mN) and a controlled drug release profile. Drug release followed Higuchi’s square-
root model. Maximum swelling of the films occurred after 1 h and 28.26% of the films eroded during the
8-h test period. Mechanical testing revealed that the MMFs displayed a greater abrasion resistance, were
more elastic and also required more energy to break, rendering them tougher and more suitable for buccal
delivery than the monopolymeric PHCl:EUD100 film. The inclusion of CHT to the film led to a more
porous surface morphology. This study confirmed the potential of the above MMFs as a promising
candidate for buccal delivery of PHCl.
In another study, the buccal permeability potential of an antiretroviral drug, i.e., Didanosine was
investigated. As the donor concentration increased from 5 to 20 mg/ml, flux values increased statistically
significantly (P \ 0.05) from 25.94 ± 1.35 lg/cm2 h to 71.57 ± 3.12 lg/cm2 h. A linear relationship (R
2 = 0.9557) between the steady-state flux and the donor concentrations of ddI indicated a passive
diffusion transport mechanism for ddI. Aloe vera gel (AV gel) was identified as a novel buccal permeation
enhancer with initial flux values increasing significantly with an increase in AVgel concentrations from
0.25 to 2%w/w. Light microscopic evaluation showed no visible differences in the thickness of the
superficial layer of the epithelium, cell architecture, and cellular alignment of the mucosa in both the
relevant control (PBS) and the treated (PBS/ddI or ddI/PBS/AVgel) mucosae. Ultrastructural analyses
showed cellular damage in mucosae treated with 1.0% and 2.0% AVGel. These cells showed increased
intercellular spacing, plasmalemma crenulation and mitochondria appeared translucent with little internal
detail. Nuclear envelopes appeared distended and chromatin compacted and unevenly dispersed. In spite
of this, desmosomal structure remained constant throughout all treatments. Data show that this
antiretroviral drug has the potential for administration via the buccal route. These results suggest that
AVgel is an effective buccal permeation enhancer, but its impact on cellular structure at concentrations
above 0.5%w/v questions the safety of its potential use at concentrations higher than 0.5%w/v.
THE CASE FOR PLEASURE
Georges M. Halpern
Distinguished Professor of Pharmaceutical Sciences, Department of Applied Biology & Chemical
Technology, Hong Kong Polytechnic University, Hong Kong
Poverty, unavailable clean water, corrupt politicians who squander public funds, pestilence, famine, wars
and other man-made or blatantly ignored plagues kill people, make them ill and sick. Unless we address
these seriously, medications will be just another pie-in-the-sky, or lipstick-on-a-pig, that will enrich the
rich and make the poor poorer. But that is not all: the elephant-in-the-room is the Placebo. I shall provide
recent references, including videos, but intend to concentrate on Pleasure proprio sensu. While stress may
make you sick and belief could make you well, there are more than self-help guides to consult—and trust.
If some foods, e.g., yogurt, have been inducted into the ‘‘Health Hall-of-Fame,’’ further scrutiny shows
that we only eat what we like, and the healthiest concoction will take a shortcut to the garbage bin if it
does not titillate our senses. Sweetness induces analgesia at all ages. Chocolate beats Prozac and wine
beats Valium—because we enjoy them! Moderate enjoyable exercise—including sex—upregulates the
immune response, while guilt will make you sick.
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When sick, a pleasant environment or flowering plants will reduce drug consumption, normalize vital
signs, and shorten the course of the malady. Happiness makes us live longer and healthier.
Pleasure is not an ‘‘extra,’’ or bonus bringing a little more soul to certain of our acts; it is a
fundamental part of our animal life. It is just as difficult to define as spirit, but nonetheless humans are
very conscious of it.
Pleasure is a potent drive, inducing forms of behavior adapted to physiological needs, e.g.,
temperature regulation and food-and-fluid intake; sensory pleasure is an incentive to useful behavior, and
maximization of pleasure the answer to physiological conflicts and a much better life. And Pleasure is
universally affordable.
FROM METHYLENE BLUE TO CHLOROQUINE TO THE MODERN
ARTEMISININ ANTIMALARIAL ARTEMISONE: DEVELOPMENT AND
CLINICAL ASPECTS
Ronald Wai Keung Wu, Ho-Wai Chan, Man-Ki Cheung, Kin-Wo Lee, Gigi Wing Chi Chan,
Richard K. Haynes
Department of Chemistry, The Open Laboratory of Chemical Biology, Institute of Molecular Technology
for Drug Discovery and Synthesis, The Hong Kong University of Science and Technology, Clear Water
Bay, Kowloon, Hong Kong. e-mail:haynes@ust.hk
The use of methylene blue by Ehrlich in 1891 represents the first example of the use of a totally synthetic
compound for treatment of malaria. Although its use subsequently languished, it triggered an analogue
search at Bayer Elberfeld in the 1920s, resulting in the development of the quinoline antimalarials
sontochin, and, with eventual completion in other hands, the analogue resochin or chloroquine. The latter
became the most successful single drug for the treatment of malaria; it was relatively well tolerated,
affordable, and was the drug of choice in the World Health Organization (WHO) Global Eradication
Program of the 1950s. However, the emergence of resistance to chloroquine that first appeared in Asia in
the 1960s led to the demise of this drug. Fortunately, in the 1970s, artemisinin was discovered by Chinese
scientists, and with the derivatives dihydroartemisinin (DHA), artesunate, and artemether have become
front-line drugs for treatment of malaria in combination therapy with longer half-life drugs.1-3 However,
artesunate is rapidly hydrolysed in vivo to DHA, and artemether is metabolized to DHA. The
artemisinins, especially DHA, elicit neurotoxicity in laboratory screens4 and the sense of the problem is
not diminished by a fatality induced by an artesunate overdose.5 Toxicity must be borne in mind,
particularly if artemisinins are to be developed against other targets where protracted doses may be
required.3 In a program designed to generate new artemisinins for use against malaria and other targets,
we have enhanced drug permeability through the attachment of polar, nonmetabolizable groups at C-10.









































The lecture commences with a historical overview of development of synthetic antimalarials given
above, provides a brief overview of current artemisinins, and then will include newer details on the
development of artemisone that covers activity against cerebral malaria in a mouse model, other parasitic
targets, and chemical behavior against various heme species including carboxy hemoglobin and
carboxyheme. The latter results lead to the demise of the heme model for mode of action.6
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DRUG/DRUG INTERACTIONS AT THE LEVEL OF PLATELET
CYCLOOXYGENASE
T. Hohlfeld, A. Saxena, K. Schro¨r, D. Hafner
Heinrich-Heine-Universita¨t Du¨sseldorf, Institut fu¨r Pharmakologie und Klinische Pharmakologie,
Moorenstrasse 5, 40225 Du¨sseldorf, Germany
Introduction Nonsteroidal antiinflammatory drugs (NSAIDs), including ibuprofen, naproxen and others,
are among the most consumed and prescribed drugs worldwide. In addition to their known negative side
effects, such as gastrointestinal ulcer and bleeding, recent studies suggested that NSAIDs may increase
the risk of vascular events by attenuating the cardiovascular protection provided by low-dose aspirin. The
mechanism of this drug/drug interaction is not well understood.
Methods In order to better explain this hypothetical interaction, we systematically analysed the
antiplatelet effect of aspirin in the presence of NSAIDs. First, a computerized model was established to
characterize the potential of NSAIDs to interfere with aspirin-induced platelet inhibition on the basis of
enzyme kinetics, simulating the competition with aspirin at the level of platelet cyclooxygenase (COX-1).
Subsequently, we experimentally substantiated the findings by studying the effect of aspirin in vitro on
aggregation and thromboxane formation of platelets collected from healthy subjects in the presence of a
broad selection of frequently prescribed NSAIDs at therapeutically relevant concentrations.
Results Mathematical simulation demonstrated that aspirin alone and high concentrations of NSAIDs
inhibited platelet inhibition by aspirin, while lower concentrations of NSAIDs, resulting in incomplete
inhibition of platelet COX-1 and thromboxane formation, largely prevented the irreversible inhibition of
COX-1 by aspirin. Thus, the model predicted that subinhibitory concentrations of NSAIDs may lower the
antiplatelet effect of aspirin.
This was confirmed by experimental studies with several NSAIDs, including ibuprofen, flufenammate,
and piroxicam, as well as selected pyrazole analgesics, such as dipyrone and propyphenazone. However,
several other NSAIDs, including diclofenac, indomethacin, and flurbiprofen, did not interfere with COX-
1 inhibition by aspirin (TX formation and aggregation). The differences between NSAIDs suggest that
there are dissimilar binding modes to the substrate binding site of platelet COX-1, resulting in a different
extent of drug/drug interaction with aspirin. Moreover, simulation as well as experimental results
suggested that the studied interaction was competitive, i.e., platelet inhibition was restored by elevated
concentrations of aspirin.
Conclusion Some NSAIDs, including ibuprofen, piroxicam, and pyrazoles interfere with aspirin at
clinically relevant concentrations. Uncritical use NSAIDs may, therefore, attenuate or abolish
cardiovascular protection by low-dose aspirin. However, there are remarkable differences between
individual NSAIDs.
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DESIGN AND DEVELOPMENT OF NEW SYNTHETIC METHODS FOR
BIOLOGICALLY IMPORTANT HETEROCYCLES
H. Ila
Jubilant Biosys Ltd., Jubilant Discovery Centre, #96, Industrial Suburb, 2nd Stage, Yeshwanthpur,
Bangalore 560 022, India
Small molecule heterocycles play an important role in drug discovery research and can exert powerful
effects on the function of macrocycles that comprise living systems. Therefore, design and development
of new pathways leading to efficient (three to five steps) synthesis of collection of small molecule
heterocycles having skeletal and functional group (appendage site) diversity is emerging as an important
area in both synthetic and medicinal chemistry. For the last several years, we have been utilizing
polarized ketene dithioacetals and the corresponding N,S-acetals derived from them as versatile building
blocks for a large number of biologically important five- and six-membered heterocycles displaying wide
range of skeletal and functional group diversity. Our recent contribution in this will be presented in the
lecture.
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GOMPHOSTENIN AND GOMPHOCRITINE: NEW ANTIMALARIAL
COMPOUNDS FROM THE NATURAL SOURCE
M. P. Kaushik
Discovery Center, Defence R & D Establishment, Jhansi Road Gwalior, MP, India
Malaria is one of the most important parasitic infections of humans due to its high morbidity and
mortality with major consequent impact on economic productivity and livelihood. Approximately 40% of
the world population lives in areas with the risk of malaria. Each year 300–500 million people suffer from
acute malaria and 1.5–2.5 million die from the disease. Plasmodium falciparum, the causative agent of the
malignant form of malaria, has high adaptability by mutation and is resistant to various types of
antimalarial drugs. Thus, low-cost malaria treatments such as chloroquine and fansidar (sulfadoxine/
pyrimethamine) become ineffective with the selection and spread of mutant drug-resistant parasites and
then to multidrug resistance emergence. Therefore, new drugs with novel mechanisms of action and that
are structurally unrelated to existing antimalarial agents are thus urgently required. The ethnopharma-
cologial approach for the search of new antimalarial has proved to be more predictive with respect to
malaria, quinine and its derivatives are still in use today, and new combination therapies based on
artemisinin were recently introduced in the clinic.
As part of our continuing efforts directed toward the discovery of the structurally interesting and
biologically active compounds from the Indian medicinal plants, three new clerodane diterpenes have
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been isolated, characterized and evaluated in vitro and in vivo for antimalarial properties against
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NOVEL POLYMERIC MICROREACTORS FOR BIO & CHEMICAL
SYNTHETIC APPLICATIONS
Dong-Pyo Kim
National Creative Research Center of Applied Microfluidic Chemistry, Chungnam National University,
Daejeon 305-764, Korea. e-mail: dpkim@cnu.ac.kr
Microreaction at lab-on-a chip system has been successfully used in synthetic, analytical chemistry, and
bio-applications. In these applications, the microfluidic devices have been generally fabricated with
durable glass, Si and metal by expensive MEMS fabrication techniques, alternatively with facile PDMS
and PMMA by soft lithography techniques but low stability. Besides, it needs to develop the novel
materials based microfluidics with high stability by facile fabrication process.
At this report, we introduce the successful fabrication of inorganic polymer-derived microchannels
with organic solvent resistance and optical transparency, via economic micromolding process. The
devices were fabricated by the commercial polysilazane, or polycarbosilane with photo- and thermal
initiators. With the niche material-based microchannels between plastic and glass device, we
demonstrated the reliable microchemical performance in various organic solvents at the different
purposes. Moreover, the Pd catalytic and photochemical reaction also was discussed. Optically
transparent inorganic polymer-derived microchannel showed excellent photocatalytic decomposition and
sterilization effect, which is useful as an alternative photochemical microreactor of glass microreactor.
And the separation process of chiral compounds in a triple laminar flow was demonstrated in the presence
of stereospecific reactive enzyme. And also our updated achievement on the alternative types of
microreactors, such as a sol–gel based hybrid resin-coated PDMS microchannel, etc. is also presented for
efficient enzymatic chemical reactions by immobilizing the enzymes on the channel surface. On the other
hand, a practical PDMS-based microchemical system with large gas–liquid contact area was successfully
demonstrated for the boron-Heck reaction with highly improved reaction yield and selectivity. The novel
polymeric microchannels can be a promising tool for various microchemistry and biotechnology
applications. Finally, we may show several types of built-in microstructured microchannels which
definitely enhance the uniqueness and performance of microfluidics.
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PROTEIN LIPIDATION INHIBITORS AS TOOLS TO STUDY CELLULAR
FUNCTION: LESSONS LEARNT FROM THE PANCREATIC BETA-CELL
Anjan Kowluru
Departments of Pharmaceutical Sciences, Medicine and Surgery, Wayne State University and John D.
Dingell VA Medical Center, Detroit, MI 48201, USA
The majority of small molecular mass GTP-binding proteins (G-proteins) and the gamma subunits of
trimeric G-proteins undergo a series of post-translational modification at their C-terminal cysteine
residue. The first committed step in this reaction sequence is the incorporation of either a farnesyl (i.e.,
15-carbon derivative of mevalonic acid; MVA) or geranylgeranyl (20-carbon derivative of MVA) groups;
these signaling steps are catalyzed by farnesyltransferase (FTase) or geranylgeranyl transferase
(GGTase), respectively. Using inhibitors of the biosynthesis of MVA (e.g., statins), a precursor for the
biosynthesis of farnesyl or geranyl geranyl pyrophosphates, we first demonstrated relevance of this
signaling pathway in glucose-stimulated insulin secretion (GSIS). Subsequent investigations from our
laboratory using pro-drug inhibitors of protein lipidation (e.g., 3-allyl or vinyl farnesols and geraniols)
yielded convincing support for regulatory roles for G-protein lipidation in GSIS. More recently, using
peptidomimetic inhibitors of FTases (e.g., FTI-277) and GGTases (GGTI-2147), we not only verified
aforementioned conclusions, but also identified specific small G-proteins (e.g., Rac1) involved in GSIS.
These pharmacological observations were further confirmed by molecular biological approaches (e.g.,
overexpression of a dominant negative mutants or siRNA-mediated knock-down of endogenous FTase/
GGTase). Together, data from investigations have clearly implicated post-translational lipidation in beta-
cell function. Potential defects (e.g., hypo/hyper regulation of these signaling steps) could contribute
toward metabolic dysregulation (e.g., increase in oxidative stress and mitochondrial defects) and eventual
demise of the islet beta-cell leading to the onset of diabetes. Potential therapeutic utility of lipidation
inhibitors in the treatment and prevention of diabetes will be discussed.
DIABETIC RETINOPATHY AND POTENTIAL THERAPEUTICS
Renu A. Kowluru
Kresge Eye Institute, Wayne State University, Detroit, MI, USA
Retinopathy is one of the most debilitating microvascular complications that affect over 80% of patients
with diabetes. Reactive oxygen species are elevated in the retina in diabetes, and this increases the
permeability of mitochondrial membranes, and their DNA is damaged. These abnormalities are
implicated in the pathogenesis of diabetic retinopathy via increasing apoptosis of retinal capillary cells.
Using animal models of diabetic retinopathy, we have shown that antioxidants that inhibit diabetes-
induced oxidative stress in the retina also have potential in preventing capillary cell apoptosis and
histopathology characteristic of diabetic retinopathy. Further, our results have shown that overexpression
of the enzyme responsible for scavenging mitochondrial superoxide (manganese superoxide dismutase)
protects retina and its capillary cells from diabetes-induced abnormalities in the mitochondria, accelerated
apoptosis and, also histopathological microvascular changes. However, clinical trials with antioxidants
are very limited in numbers, and have produced somewhat ambiguous results. Although antioxidants are
being used for other chronic diseases, controlled clinical trials are warranted to investigate the potential
beneficial effects of antioxidants in the development of retinopathy in diabetic patients.
BIOMOLECULAR CHEMISTRY DIRECTED TOWARDS DRUG
DEVELOPMENT
Rene´ Martin,1 Juliane Kirst,1 Sebastian Weidlich,1 Heinke Schieb,1 Georg Schlechtingen,1,3 A. Ja¨ger,1
Lawrence Rajendran,4 Markus Bo¨hl,5 Sabine Richter,5 Roman Fedorov,6 Dietmar J. Manstein,6 Herwig
O. Gutzeit,5 Hans Klafki,2 Jens Wiltfang,2 Kai Simons,3,4 Hans-Joachim Kno¨lker1,3
Med Chem Res (2010) 19:S3–S41 S23
1Department Chemie, Technische Universita¨t Dresden, Bergstr. 66, 01069 Dresden, Germany.
e-mail: hans-joachim.knoelker@tu-dresden.de; 2Rheinische Kliniken Essen, Universita¨t Duisburg-Essen,
Virchowstr. 171, 45147 Essen, Germany; 3JADO Technologies GmbH, Tatzberg 47-51, 01307 Dresden,
Germany; 4Max Planck Institut fu¨r Molekulare Zellbiologie und Genetik, Pfotenhauer Str. 108, 01307
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Dresden, Germany; 6Institut fu¨r Biophysikalische Chemie, Medizinische Hochschule Hannover, 30623
Hannover, Germany
Alzheimer’s disease (AD) is a neurodegenerative disorder leading to progressive loss of memory and
other cognitive abilities. Currently, there is no treatment for AD available which either stops the
progress or can cure the disease. In cooperation with JADO Technologies (Dresden), the Max-Planck
Institute for Molecular Cell Biology and Genetics in Dresden and the Laboratory for Molecular
Neurobiology at the University Duisburg-Essen, we are developing an approach for the design of
potential novel drugs against AD. Characteristic of AD is the formation of extracellular aggregates of
b-amyloid peptides, known as amyloid plaques. According to the amyloid cascade hypothesis, b-
amyloid peptides are believed to play a key role in the pathogenesis. The b-amyloid peptides are
generated from the membrane protein APP (amyloid precursor protein) by sequential cleavages of APP
involving first, b-secretase, and subsequently, c-secretase. Thus, highly efficient inhibition of the b-
secretase enzyme should lead to a potential therapy for AD. Amyloidogenic cleavage of APP takes
place when APP and b-secretase are co-internalized into the cell via endocytosis. b-Secretase is found
in structural microdomains of the cell membrane, known as lipid rafts and cleavage of APP by b-
secretase was reported to occur in lipid rafts. Based on these findings, we have designed and
synthesized a modified lipophilic b-secretase inhibitor with a tripartite structure, in which each unit







The known b-secretase inhibitor GL 189 (Calbiochem) is a transition state inhibitor showing only a
minor effect in cellular assays.2 However, linking it to a membrane anchor via a spacer of defined length,
leads to a tripartite structure which locates the b-secretase inhibitor to lipid rafts. The tripartite structure is
transported into the cell by endocytosis and delivered to endosomes where b-secretase is active.1,3 The
first results emphasized that our tripartite structures are more effective compared to nonlipophilic
modified inhibitors, by several orders of magnitude—in cell culture as well as in animal models. In a
mouse model simulating AD, our novel inhibitor reduced the formation of b-amyloid peptides by 60% in
only 4 h, whereas the nonanchored inhibitor showed no effect.
Pentabromopseudilin (1): R1 = R2 = Br
Pentachloropseudilin (2): R1 = R2 = Cl
Tribromodichloropseudilin (12): R1 = Cl, R2 = Br
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In a further project, we are developing novel inhibitors of myosin ATPase. Based on a silver-
mediated pyrrole synthesis described a few years ago,4 we have elaborated a highly efficient silver-
catalyzed route which provided pentabromopseudilin (1) and pentachloropseudilin (2), halogenated
natural products isolated from microorganisms, as well as their synthetic analogs 12 and 14.5 These
compounds have been identified as novel isoform-specific inhibitors of myosin motor activity. The
activities of 1 and 2 are comparable to the known inhibitors (-)-blebbistatin (17) and N-benzyl-p-
toluenesulfonamide (BTS) (18).5-7























An X-ray crystal structure analysis of the complex formed by the Dictyostelium myosin-2 motor-
domain with Mg2?–ADP–meta-vanadate and pentabromopseudilin (1) revealed a new allosteric binding
site, 7.5 A˚ away from the allosteric binding site of (-)-blebbistatin (17).
The discovery of a novel class of myosin ATPase inhibitors and the identification of a second
allosteric-binding site opens up the way for the development of more potent isoform-specific myosin
inhibitors based on rational drug design. Specific inhibitors of myosins represent promising candidates for
the treatment of a range of diseases, such as cancer and malaria.
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GOING AFTER THE OBVIOUS: INHIBITORS OF DE NOVO
NUCLEOTIDE SYNTHESIS PATHWAY
Lakshmi P. Kotra
Scientist and Principal Investigator, Toronto General Research Institute; Director, Center for Molecular
Design and Preformulations, University Health Network and University of Toronto, Toronto, ON M5G
1L7, Canada
Pyrimidine nucleotides are building blocks for the synthesis of RNA and DNA. Uridine monophosphate
(UMP) serves as a key intermediate in the de novo pathway for the synthesis of pyrimidine nucleotides.
Orotidine monophopshate decarboxylase (ODCase) is an important and efficient enzyme that
accomplishes the ultimate step for the synthesis of UMP. Due to its important role in the de novo
nucleic acid biosynthesis, ODCase is present in every species including bacteria, parasites such as
plasmodia and humans, but not in viruses. In humans, pyrimidine nucleotides are synthesized via two
routes: de novo and salvage pathways. Whenever higher concentrations of pyrimidines are needed in the
cell including for the normal cellular processes, during uncontrolled growth of the cell such as in cancer,
or during the fast replicating viral infections, etc., de novo pyrimidine synthesis is upregulated, and the
activity of ODCase is simultaneously operating at a higher than normal levels. Our group has been
interested in developing novel inhibitors of this enzyme as potential antiviral agents initially, and
synthesized various C6-substituted pyrimidine nucleosides and nucleotides.
Initially, in collaboration with Emil Pai, we discovered that certain substitutions such as iodo and
azido moieties would create covalent inhibitors to ODCase. Other substitutions such as a methyl or amino
moieties would confer potent ODCase inhibitory properties to these molecules. Subsequent in vitro
evaluation targeting malaria revealed that ODCase inhibitors could be potentially novel class of
compounds targeting malaria. Select inhibitors also exhibited potent anticancer activities against cancers
of hematopoietic origin. A collaborative effort is undertaken to further investigate the potential of
ODCase inhibitors as potential antimalarial and anticancer agents, in vitro and in vivo. This talk will
focus on the discoveries on the novel interactions between the ligands and the enzyme, and our efforts to
develop this class of compounds as potential leads.
METABOLITES—INSIGHTS INTO MICROBIAL DEFENCE SYSTEMS
Hartmut Laatsch
Institute of Organic and Biomolecular Chemistry, University of Go¨ttingen, Tammannstr. 2,
37077 Go¨ttingen, Germany. e-mail: hlaatsc@gwdg.de
Natural products are words and messages in a global communication system of species interactions. They
have a special meaning and will effect an answer, which is not urgently constant, but depends on the
given situation. Natural products are weapons and defence systems, attractants or repellents, or just
communication signals, which are important for the survival of species. Also resistance development of
bacteria against antibiotics is such a logical and unavoidable reply, which we can only overcome with a
better vocabulary, i.e., with more and better drugs.
It follows that a continuous and efficient search for new natural products with potential application in
medicine is a steady and indispensable task. However, since the number of natural products is limited,
every newly isolated product will diminish the chances of further research. Two techniques have been
applied to overcome this problem. One is the activity-directed high-throughput screening, which is an
expensive and technical, but less intelligent process; the other one is the chemical screening.
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We are using a third one, a type of dragnet investigation, where we compare easily accessible data of
more than 50,000 marine and microbial natural products from our databases, AntiBase or MarinLit, with
our isolated and purified compounds. Comparison of substructures, NMR, MS, and UV data allows a very
fast decision as to whether a given natural product is already known or not, which enables us to save time
and money and avoid frustration.
New natural products often have existing parallels, which can be found with the same techniques.
Others compounds are classified via their TLC/UV data or with our ESI MS/MS fragment libraries
directly from crude extracts.
Fig. X-ray structure of gutingimycin
The presentation will explain modern dereplication techniques using recent examples from our
ongoing research on marine bacteria. Database mining using HPLC/MS2, TLC/UV, and TLC/DESI-MS
techniques will be compared.
CYTOTOXIC REACTIVE CARBONYL SPECIES (RCS): FROM
METABOLIC STUDIES TO THE DISCOVERY OF NOVEL RCS
SEQUESTERING AGENTS
Marica Orioli, Marina Carini, Giancarlo Aldini
Department of Pharmaceutical Sciences ‘‘P. Pratesi’’, Universita` degli Studi di Milano, Via Mangiagalli
25, 20133, Milan, Italy. e-mail: marica.orioli@unimi.it
Reactive carbonyl species (RCS), such as a,b-unsaturated aldehydes [4-hydroxy-trans-2-nonenal (HNE),
acrolein (ACR)], dialdehydes [malondialdehyde (MDA), glyoxal (GO)], and levuglandines are important
cytotoxic mediators leading to alteration of the cellular function and involved in several physiopath-
ological conditions including diabetic-related diseases, age-dependent tissue dysfunction, and metabolic
distress syndrome. The main detoxification pathways of RCS involve oxidation–reduction of the carbonyl
function, and glutathione (GSH) conjugation by GSH-S-transferases. More recently, by using a
peptidomic mass spectrometric approach, we identified endogenous histidine dipeptides, such as
carnosine (b-alanyl-L-histidine, CAR), as additional nucleophilic agents able to detoxify the a,b-
unsaturated aldehydes through a Michael adduction.1 This novel metabolic pattern has been then
confirmed in vivo in the Zucker obese rats, a well-established animal model of carbonyl damage, by
detecting in urine the Michael adduct CAR-HNE. When RCS are massively generated, or when the
detoxification systems are hampered, RCS covalently react with several macromolecules such as DNA
and proteins, leading to cell and tissue damages. Hence, RCS are a potential drug target and there is great
interest in searching novel bioactive molecules effective in detoxifying these compounds through a direct
mechanism (RCS sequestering effect), or by restoring/ameliorating the metabolic efficiency.2 Although
CAR is a selective and endogenous quencher of RCS, its pharmacological use is limited since it is rapidly
hydrolyzed by a specific serum dipeptidase (carnosinase). Hence, we were aimed to derive CAR
analogues characterized by (i) carnosinase stability and (ii) a greater reactivity toward RCS, even
maintaining the same selectivity. The stability was reached by the isomerization of L- to D-histidine,
leading to b-alanyl-D-histidine (D-carnosine, D-CAR), which is not recognized by carnosinase, but
maintains the same quenching activity of L-CAR. The increase of reactivity was reached by modulating
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the conformational profile of the Schiff’s base intermediate, in order to favor a close conformation in
which the imidazole ring approaches enough the C3 of the Schiff’s base to form the corresponding
Michael adduct. A series of D-CAR derivatives was analyzed by in silico approaches to find out those
characterized by a favorable folded conformational profile. The most promising was synthesized and the
stability and quenching ability evaluated. By this way, a set of phenyl derivatives was identified,
characterized by high stability in human plasma, and by a nearly doubled HNE-quenching ability
compared to D-CAR.
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POLYCYCLIC CAGE STRUCTURES AS LIPOPHILIC SCAFFOLDS FOR
NEUROPROTECTIVE DRUGS
Sarel F. Malan
School of Pharmacy, University of the Western Cape, Private Bag X17, Bellville, South Africa and School
of Pharmacy, North-West University, Potchefstroom, South Africa. e-mail: sfmalan@uwc.ac.za
The lethal triplet of metabolic compromise, oxidative stress, and excitotoxicity may act separately or
cooperatively to cause neuronal cell death. Intracellular calcium homeostasis, or rather the lack thereof,
has in many studies been implicated in neuronal degeneration and is currently believed to be one of its
main causes. Intracellular calcium overload leads to the activation of various enzyme systems, as well as
intracellular accumulation of free radicals and thus oxidative stress. These and other calcium-related
processes ultimately lead to cell death and neurodegeneration. Earlier studies evaluating the biological
activity of the polycyclic cage amines indicated activity that includes amongst others, L-type calcium
channel antagonism—leading to possible neuroprotective activity—and high affinity for the sigma-
binding site. The potential antiparkinsonian and neuroprotective activity of the pentacycloundecylamine
and D3-trishomocubane derivatives was demonstrated in the MPTP parkinsonian mouse model and is
thought to reside primarily in the observed sigma receptor antagonism and ion channel modulating effects
thereof. Inhibition of the dopamine transporter could also be of importance in this model. Based on this
information and the structural similarities of the polycyclic cage amines and memantine, a series of
functionalized cage compounds was synthesized and evaluated for neuroprotection through various, and
possibly dual or multiple mechanisms. The highly lipophilic polycyclic cage was also utilized in a
prodrug strategy to afford blood–brain barrier permeability to drugs with known antioxidant and possible
neuroprotective potential.
In these studies, the polycyclic cage has proven to be a excellent scaffold for design of neuroprotective
compounds and it is postulated that derivatives thereof could yet be of therapeutic value in the treatment
of neurodegenerative disorders like Parkinson’s and Alzheimer’s disease.
TELOMERE LENGTH MAINTENANCE AS A TARGET FOR
ANTICANCER DRUG DISCOVERY
K. Muniyappa
Department of Biochemistry, Indian Institute of Science, Bangalore 560012, India
Telomeres are distinctive structures, composed of tandemly repeated DNA sequences and associated
proteins that cap the ends of all eukaryotic chromosomes. Telomeres are essential for maintaining the
integrity and stability of eukaryotic genomes. In mammals, the length, structure, and function of telomeres
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have been believed to contribute to cellular and organismal phenotypes associated with cancer and aging.
Telomere length is regulated by telomerase-dependent and telomerase-independent mechanisms. Drugs
that directly bind to the telomeres and stabilize secondary DNA structures such as G-quadruplexes are
potent inhibitors of telomerase; consequently, these could serve as new targets for cancer therapy. I will
discuss what is known about the basis for the links between telomeres, aging and cancer, and some of the
known and proposed consequences of telomere dysfunction in normal and cancer cells
NATURE—A VALUABLE PLATFORM FOR NEW DRUG DISCOVERY
M. D. Nair
Formerly Vice President, SPIC Pharmaceuticals, A-11, Sagarika No. 15, 3rd Seaward Road, Valmiki
Nagar, Thiruvanmiyur, Chennai 600 041, TN, India. e-mail: e-mdnair@vsnl.com
The global R&D based pharmaceutical companies which have been responsible for the discovery,
development, manufacture, and distribution of new drugs to the patients who need them, is today at the cross
roads. While trying to re-establish its ability to survive and grow in an environment of declining pipelines of
new products, low productivity, escalating costs, low returns due to decrease in exclusivity for products in
the market place due to patent expiries, fast eroding public image, and pressure on costs and prices, it is
obvious that an introspection of its current business and R&D models has become imperative.
While many new models for drug discovery are being actively pursued by the R&D based
pharmaceutical companies including systems biology and modern genomics and proteomics based
approaches, they are yet to deliver novel drugs or drug leads in any significant way. In addition, there is
no indication that these approaches have the potential to reduce the costs of drug discovery and
development and speed up the process to provide drugs which are more affordable to the masses.
In the history of new drug discovery, natural products, primarily plant-based ones have played a major
role. However, due to lack of sustained scientific efforts, low success rates, complex nature of candidate
drugs, and difficulties in patenting the products due to their origin being natural resources, for the last five
decades there has been a decline in interest. In this area in recent times due to the very poor pipeline for
new drugs in spite of massive investments, disillusionment of chemicals based drugs, back to nature
attitudes, better understanding of disease processes, relaxation of regulatory requirements for plant-based
drugs and the long track record of safe use of such drugs in traditional systems of medicine, there is a
resurgence of interest in exploring the vast potential that these approaches offer. Since the sixties, for the
next four decades, except for Paclitaxel and artemesinin, very few products including antibiotics have
been discovered and developed from natural products. However, during the period 2005–2007, 13 new
drugs of which five are first members of new classes were approved by the U.S. FDA. Even by modern
standards, natural products are the largest depository of combinatorial libraries which for sheer numbers
and diversity, can never be replicated through chemical means. With appropriate in vitro and in vivo
screening models, it is possible to discover new drugs from natural products to complement the available
therapies and meet unmet medical needs.
This presentation will dilineate a very practical, scientific and integrated approach to exploit natural
products for the discovery of novel drugs for diseases for which no satisfactory therapy is available or the
available ones are unsuitable or inadequate.
APPRAISAL OF OZONE AS BIOLOGICALLY ACTIVE MOLECULE AND
EXPERIMENTAL TOOL IN BIOMEDICAL SCIENCES
Douglas W Oliver, Christiaan B. Brink, Brian H. Harvey, Mmalebuso L Mokoena
Unit for Drug Research and Development, School of Pharmacy, North-West University Potchefstroom
Campus, Private Bag X6001, Potchefstroom 2530, South Africa
Ozone (O3) is a major air pollutant and is well-known for its very strong oxidative actions with beneficial
effects in purifying various matrixes resulting in a variety of potential uses, in view of its antimicrobial
and deodorizing properties. Ozone is frequently used for chemical industrial applications replacing
chorine as a purifying and sterilizing agent for matrixes such as air, water, and soil. In recent years, there
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has been an ever increasing interest in ozone for its beneficial potential in biological systems. Ozone also
converts to reactive oxygen species (ROS) upon contact with biological membranes, which ultimately are
responsible for its systemic oxidative effects. On the other hand, ozone has been proposed as a cellular
metabolic activator and immunomodulator. Numerous reports have entered the literature on the medicinal
application of ozone in alternative medicine. The majority of the data from these reports on the clinical
application of ozone in the human has come from uncontrolled investigations. Medicinal claims are made
as far reaching as amongst others the ozone treatment of HIV/AIDS.
The concerns viewed during several international forums in recent years on the safety and potential
inappropriate medicinal use of ozone prompted us to conduct several investigations on the biological
activity of ozone. Experimental design was performed to administer ozone acutely and chronically to
intact test animals in in vivo exposure models to investigate and provide evidence of proof of concept of
such animal models for ozone treatments. The successful experimental model design allowed for the dose
and time investigations of inhaled ozone. These controlled ozone studies demonstrated that the model is
effective to investigate the biological activity of ozone as well as the mechanisms involved in the ozone-
induced oxidative stress in both normal- and disease-induced animals. These studies also indicated that
the responses after ozone treatments differ in a concentration-dependant manner with respect to acute
versus chronic treatments.
In conclusion, these investigations not only yielded information on the safety and biological activity
of ozone, but also provided evidence that ozone is a unique pharmacological and toxically experimental
tool for investigations that involves oxidative stress conditions in biological systems. The data from these
studies further emphasize caution for the systemic used of ozone for medicinal purposes view of its
complex activities and actions.
COMPUTER-ASSISTED PREDICTION AND DESIGN OF
MULTITARGETED DRUGS
Vladimir Poroikov
Institute of Biomedical Chemistry of Rus. Acad. Med. Sci., 10, Pogodinskaya Str., Moscow 119121,
Russia. e-mail: vladimir.poroikov@ibmc.msk.ru
During the XX century, the dominant paradigm in creation of new drugs was based on suggestion about
selectivity of action on a certain molecular target, which should lead to the normalization of pathological
process. At the same time, the majority of known drugs interact with several or even many targets in the
organism; however, such action is mostly associated with unwanted adverse effects and toxicity.
After the deciphering of human genome and first results achieved in postgenomic studies, it became
obvious that many diseases have a complex etiology, while drug action on a certain target often leads to
activation/blockade of other elements in the appropriate regulatory network. As a consequence of
negative feedbacks, expected pharmacotherapeutic action may be significantly decreased or even
completely suppressed. The multitargeted drugs concept appears, according which such remedies due to
the additive, synergistic, or antagonistic action might have some advantages comparing to the
monotargeted medicines.
Discovery of new multitargeted drugs requires the solution of two tasks: (1) identification of targets
which could be blocked or activated to achieve the desirable pharmacotherapeutic effect, and (2) finding
of ligands that interact with the identified targets in a desirable mode. The first aim could be achieved by
simulation of behavior in regulatory network blocking or activating certain nodes (targets) and their
combinations. The second aim could be achieved either by prediction of biological activity spectra for
molecules from different databases and selection of hits with the requested biological profiles, or by direct
computer-aided design of multitargeted ligands. Possibilities and limitations of current bioinformatics and
computer-aided drug design methods in discovery of particular molecular targets and their multiple
ligands will be discussed.
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NANOPLATFORM FOR TUMOR IMAGING AND THERAPY
Ravindra K. Pandey
Photodynamic Therapy Center, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Both cancer detection and treatment depend on selective delivery of appropriate agents to the malignancy.
Photodynamic therapy (PDT), a relatively new modality for the treatment of a variety of oncological,
cardiovascular, dermatological, and ophthalmic diseases, is based on the preferential localization of
photosensitizing molecules (PS) in target tissue. Upon light absorption, the PS produces reactive singlet
oxygen which damages tumor cells and neovasculature, and also initiates anti-tumor inflammatory and
immune responses. We and others have developed relatively tumor-avid PS which selectively
accumulates in tumors in vivo, and these molecules have been used to carry optical, PET, and MR
imaging agents to the tumor sites. However, the tumor selectivity of current PS is not always adequate.
Approaches of linking PS to antibody fragments or receptor ligands have been disappointing because the
number of required PS/cell generally is lower than the number of antigen- or receptor-binding sites.
Conversely, the imaging agent carrying capacity of individual PS molecules is limited.
Nanotechnology platforms potentially can deliver large numbers of PS and/or imaging agents to
tumors. Nanoparticles (NP) are uniquely promising in that (i) their hydrophilicity and charge can be
altered; (ii) they possess enormous surface areas and their surface can be modified with functional groups
possessing a diverse array of chemical and biochemical properties, including tumor-selective ligands; (iii)
owing to their subcellular and submicron size, they can penetrate deep into tissues and generally are taken
up efficiently by cells; (iv) since numerous strategies for the preparation of nanomaterials are already in
place, PS-loaded nanoparticles can be made by numerous methods, such as covalent linkages or self-
assembly.
For the last 5 years, we have been working on biocompatible organically modified ormosil and
polyacrylamide nanoparticles, which can be used to develop multifunctional nanovectors for tumor
therapy and imaging (optical and PET) in injectable formulations for safe and efficient trafficking to
tumor tissues in vivo.
We have collected strong supporting evidence for the vision of the comprehensive development,
characterization, and validation of multifunctional nanovector platforms that can deliver tumor-avid
therapeutic photosensitizers that are only active (and toxic) when illuminated by specific wavelengths of
light, and also carry one or more imaging agents; thus enabling both multimodal diagnosis and image-
guided therapy. Tumor selectivity is achieved from the tumor avidity of the PS and/or from peptide
ligands recognized by target cells as well as from the local activation of the PS. The synthesis and
biological significance of these nanoparticles will be presented.
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OMARKERS AS SURROGATE ENDPOINTS IN CLINICAL TRIALS
Bernd Rosenkranz
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A biomarker (BM) is ‘‘a characteristic that is measured and evaluated as an indicator of normal biological
processes, pathogenic processes, or pharmacological responses to a therapeutic intervention’’ (FDA-NIH
Consensus Conference 1999). BMs can reduce cost and duration of drug development. During early clinical
development, they are useful for demonstrating ‘‘proof of concept,’’ for selecting the best clinical candidate
or for dose finding. A BM can be qualified to the status of a surrogate endpoint (SEP) ‘‘that is intended to
substitute for a clinical endpoint and that is expected to predict clinical benefit (or harm, or lack of benefit or
harm) on the basis of epidemiological, therapeutic, pathophysiological, or other scientific evidence’’
(Biomarker Definitions Working Group 2001), if the following conditions are met: (a) biological
plausibility, (b) statistical relationship between surrogate and clinical outcome, and (c) treatment effects on
the surrogate correspond to outcome in clinical studies. Examples for efficacy SEPs include CD4 count/
HIV1 viral load for ARVs, tumor imaging or progression-free survival for chemotherapy, blood pressure or
LDL for cardiovascular drugs, or HbA1c for antidiabetics. QTc, a safety SEP for sudden death due to
‘‘torsades de pointes,’’ has become a mandatory FDA requirement for NDA submissions.
Several biologically plausible BMs have been shown not to be related to the proposed associated
clinical endpoints. For example, premature ventricular contractions after myocardial infarction were
considered to be a key trigger of sudden cardiac death. Very unexpectedly, however, a large clinical trial
(CAST 1991) revealed that treatment with class 1 antiarrhythmics led to a significant increase in mortality
in this patient population. Other examples for failures of SEPs include bone mineral density to predict
osteoporotic fractures across drug classes, or negative inotropic effect of betablockers to predict an
unfavorable outcome in congestive heart failure. Appropriate qualification and validation of BMs are
absolutely mandatory for their successful use as SEP in drug development. Both FDA and EMEA have
recognized the continued need for addressing this topic. As of 2009, the FDA sponsors a project
‘‘Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease’’ together with the US Institute
of Medicine (HCSX-H-08-06-A); in the same year, the EMEA have formalized a new Scientific Advice
procedure for qualification of biomarkers in a research and development context.
LIPOTEICHOIC ACIDS OF GRAM-POSITIVE BACTERIA—SYNTHESIS
AND SOME BIOLOGICAL PROPERTIES
Richard R. Schmidt
Fachbereich Chemie, Universita¨t Konstanz, Fach 725, 78457 Konstanz, Germany. e-mail:
richard.schmidt@uni-konstanz.de
Gram-positive bacteria are causing many infectious diseases; nevertheless, these bacteria are not as well
understood as gram-negative bacteria. It is assumed that amongst the immunoactive constituents of gram-
positive bacteria are lipoteichoic acids (LTAs). They are amphiphilic, negatively charged, structurally quite
different glycolipids that were classified into four types (type I–IV). The most frequently isolated gram-
positive pathogen causing infections is Staphylococcus aureus possessing an LTA classified as type I that
has been synthesized in our group and biologically evaluated. LTAs that also gained great interest are type II
LTA isolated from Lactococcus garvieae and particularly type IV LTA 1 isolated from Streptococcus
pneumoniae, respectively. All three LTAs are structurally quite different, but they are believed to interact
with the innate immune system in a similar fashion, which is by stimulation of TLR2. Hence, chemical




























































1:   X = NH3+, NHAc; R = H, D-Ala, α-GalNAc
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DOMINO AND CHIRAL POOL APPROACHES FOR BIOLOGICALLY
ACTIVE NATURAL PRODUCT SYNTHESIS: TOWARDS NEW
PHARMACOPHORES
Sime´on Arseniyadis
Centre de Recherche de Gif, Institut de Chimie des Substances Naturelles, CNRS, 91198 Gif-sur-Yvette
Cedex, France. e-mail: simeon.arseniyadis@icsn.cnrs-gif.fr
Around 50% of antibiotic, antitumor, antiviral, immunosuppressants, anticholesterol, antidiabetic drugs
derive from secondary metabolites. The iridals comprise several families of monocyclic, bicyclic, or
spirocyclic A-seco triterpenes that have in common a central B-ring nucleus. Discovered by Marner et al.,
they show a broad range of biological activities including anti-tumor, MDR reversal, antiplasmodial,
membrane reinforcing, and protein kinase C activation.1 Galbanic acid, itself an A-seco sesquiterpene
coumarin ether, shows a range of biological activities such as antibiotic, antibacterial, antithrombotic, and
hepatoprotective activities.2 The compound is also a potent antifertility and hormonal lead. It was
demonstrated to synergize with various antibiotics opening up promising applications for the treatment of








































Very recently, methyl-galbanate and galbanic acid were screened in an in vitro anti-influenza A viral
(H1N1) assay, with amantadine (IC50 0.92 mg/ml), as a positive control. They are reported to show good
potency against influenza A virus H1N1 (IC50 0.26 and 0.45 mg/ml), with the methyl-galbanate showing
better potency than its corresponding free acid. Sesquiterpenes from Celastraceae are promising
candidates in cancer chemotherapy. The interesting biological profile of these natural products, along
with their challenging molecular structures, led us to embark on their synthesis. Compounds accessed
from these endeavors are candidates for pharmaceutical development in the area of antiproliferating
activity, malaria, influenza, fertility control, and combined therapy. Since both targeted families (iridals-
galbanic acid) fall within the boundaries of Lipinski’s rules, prospects for pharmaceutical development
are promising, once lead compounds have been identified. Routes toward the target structures in this
project were designed in such a way as to allow structural simplification and variation of the natural iridal
and galbanic acid framework. To the best of our knowledge, there have been no studies on the mode of
action of iridal and its congeners at the molecular level, since there is no literature report on systematic
SAR work for iridals so far. Bearing a significantly less complex structure compared with taxol, and
therefore easier to synthesize, iridals could represent new chemotypes for microtubule inhibition. Within
the time limits, iridal,3 marneral (the biogenetic precursor of all iridals), and galbanic acid4 syntheses will
be presented in reasonable detail.
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FIGHTING AGAINST TUMOURS
Giovanni Petrillo,1 Domenico Spinelli,2 Maurizio Viale3
1Dipartimento di Chimica e Chimica Industriale Universita` di Genova, Via Dodecaneso 31, 16146
Genova, Italy. e-mail: petrillo@chimica.unige.it; 2Dipartimento di Chimica ‘G. Ciamician’ Universita` di
Bologna, Via Selmi 2, 40126 Bologna, Italy. e-mail: domenico.spinelli@unibo.it; 3Istituto Nazionale per
la Ricerca sul Cancro, S.C. Terapia Immunologica, Largo R. Benzi 10, 16132 Genova, Italy. e-mail:
maurizio.viale@istge.it
Different strategies are normally used in the fight against tumours. In the presence of localized
malignancies surgery and radiotherapy are usually effectively employed. In contrast, the occurrence of
metastatic tumours requires treatment based on chemotherapy supported by immunotherapy or by
modifiers of biological response, often able to improve the response rate at least in selected cases.
Notwithstanding the efforts in this field and some unquestionable improvements, the chemotherapy’s
effectiveness is still quite low for most cancer types such as ovary, colon, lung, kidney, pancreas, and
liver cancers. Perhaps the most important cause of failure depends on the development of intrinsic and
acquired drug resistance by the tumour cells that causes disease relapse because of some specific or more
general cellular mechanisms which provide tumour cells with the ability to resist chemotherapy.
To gain more and more instruments in the fight against tumours, we have developed the synthesis of
new compounds able to behave as potential antitumor drugs or promising lead structures and also of new
compounds able to contrast the phenomenon of multidrug resistance (MDR).
In the lecture, the synthesis of some relevant classes of compounds will be described and some recent
results on their biological activities illustrated.
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SWEETNESS AND LIGHT: CONTINUOUS GLUCOSE SENSING AND
REAL TIME ENZYME ASSAYS USING BORONIC ACID APPENDED
VIOLOGENS
Bakthan Singaram
Department of Chemistry and Biochemistry, University of California at Santa Cruz
Carbohydrates and their derivatives, including saccharides, phosphosugars, and nucleotides, are
ubiquitous metabolites in every organism. Sensitive probes for monitoring the presence of these
metabolites provide researchers a powerful tool to elucidate biological processes. Our group has
extensively developed fluorescent probes for metabolites including glucose, phosphosugars, and
nucleotides. We have developed a two-component optical probe with a modular receptor scaffold. This
small molecule probe is water-soluble, and operates in the blue-green region of the spectrum. Saccharide
recognition in our probe system is achieved with a boronic acids appended viologen that serves as an
analyte responsive fluorescence quencher. We used an anionic dye which forms a weakly fluorescent
complex with the cationic viologen receptor. At and near physiological pH, saccharide binding by the
receptor results in a partial charge neutralization of the viologen. This produces an increase in the
fluorescent signal dependent on glucose concentration. Incorporating the probe into a hydrogel polymer
allowed for continuous monitoring of glucose concentrations in the physiological range. In another
application, an array of probes with differential selectivity was used to discriminate important
carbohydrate metabolites in water in multiwell plates and to assay enzymes involved in glycolysis.
15-DEOXYSPERGUALIN PRIMARILY TARGETS THE TRAFFICKING
OF APICOPLAST PROTEINS IN PLASMODIUM FALCIPARUM
T. N. C. Ramya,1 Avadhesha Surolia,1,2 Namita Surolia3
1Molecular Biophysics Unit, Indian Institute of Science, Bangalore 560 012, India; 2National Institute of
Immunology, Aruna Asaf Ali Marg, New Delhi 110 006, India; 3Jawaharlal Nehru Centre for Advanced
Scientific Research, Bangalore 560064, India
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15-Deoxyspergualin (DSG) has tumoricidal, immunosuppressive, and antimalarial properties. However,
the mechanism of its antimalarial action remains obscure as DSG inhibits a diverse array of cellular
processes ranging from a decrease in cellular cytochrome c oxidase activity to depletion of polyamines.
To this end, we investigated its effect on Plasmodium falciparum protein synthesis, polyamine
biosynthesis, and transport. DSG abrogated protein synthesis in P. falciparum by Hsp70 sequestration and
subsequent phosphorylation of the eukaryotic initiation factor eIF2a. However, DSG invoked inhibition
of protein synthesis as well as polyamine biosynthesis and/or its transport only at *1000-fold higher
levels than the submicromolar concentrations at which it was effective as an antimalarial agent.
Subsequent experiments demonstrate that DSG specifically disrupts the trafficking of nuclear-encoded
apicoplast-targeted (NEAT) proteins to the apicoplast. To our knowledge, this is the first report of delayed
death resulting from the inhibition of NEAT protein trafficking by a small molecule. These studies also
provide a small molecule to dissect the targeting of nuclearly encoded proteins to apicoplast. Our study
not only identifies the primary target of DSG in the malaria parasite, but also uncovers a novel and
extremely potent inhibition of a hitherto unexplored apicoplast function.
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MEDICINAL CHEMISTRY: AN EVER EVOLVING DISCIPLINE
Henk Timmerman
VU University Amsterdam, The Netherlands
Medicinal chemistry may be defined as the art to design—and subsequently to synthesise and
pharmacologically characterise—on basis of information on structure-property relationships new
compounds which should have the right pharmacological and toxicological profile for being suitable
as active ingredient in medicinal products.
For obvious reasons, medicinal chemistry could only emerge when organic synthesis became possible;
that was around 1855. Until than medicinal products were derived either from biological sources (mainly
plants) or metal oxides or salts. The first class contained mainly inactive or only weakly active
preparations, the second could be described as especially toxic products. When synthetic medicines were
introduced, scientists realized that the chemical properties should be seen as also responsible for their
biological effects; structure–activity relationships were already in the 1880s studied! There was an early
euphoria and some investigators expected that soon ‘‘medicines could be designed (!!) for any disease.’’
That was before 1900.
Things developed in a much different way. It was organic chemistry which determined for a long
period the progress in medicinal chemistry. Organic chemists synthesised new derivatives which were
accessible and pharmacologists searched for useful properties by screening procedures in vivo. Finding
new useful compounds was a matter of trial and error and especially luck. Around 1935, the famous
pharmacologist Clark sighed, ‘‘we have studied structure–activity relationships so intensively that we
have a fair knowledge about the extend of our ignorance.’’ The reasons for the failures were manifold,
but especially the absence of useful parameters for biological activities made it impossible to derive at
useful insights into the relationships between chemical structure and biological property of organic
molecules.
When in the 1960s, pharmacology changed into in vitro methods and molecular pharmacology was
introduced pharmacology (better pharmacological parameters) started to become responsible for progress
in medicinal chemistry; so-called selective compounds became attractive. When somewhat later in time
computers became available for complex calculations, a boost in the studies structure–activity
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relationships could be observed. QSAR became a trendy approach and again scientist predicted that it
would become relatively easy to design new medicines.
The results of applying the new methodologies were disappointing. The reason was a very intrinsic
problem when trying to arrive at new medicines. A medicine cannot be described by one single property.
Of course, an active ingredient of a medicine should have a certain property—such as a stimulatory or a
blocking effect for a given receptor, but it should also have certain pharmacokinetic properties, other
activities should be absent (side effects) and the toxicity profile should at least guarantee a good
therapeutic window. Currently, it is more or less possible to design compounds having a predicted
property, but that is not sufficient for making useful medicines.
During more recent years, it has been the introduction of molecular biology, the advancement in
analytical technologies, the emerging of systems biology, the availability of extremely powerful
computers which determine the enormous progress in the possibility to derive at very interesting
compounds, A major hurdle remains, however, the complexity of the profile of any compound for making
it useful for medicinal applications. This truly intrinsic problem is a very tough one and one might
therefore have some doubts whether it will ever be possible to design a new medicine.
In this presentation, historical aspects will be presented, together with a personal opinion about
coming developments. An essential characteristic of medicinal chemistry will receive special attention;
the field can only flourish an approach in which several disciplines are integrated. The meaning of this
conclusion for teaching and training medicinal chemistry will be emphasized as well.
SYNTHESIS AND/OR REACTIVITY OF NOVEL PYRROLE, INDOLE, 1,2-
BENZISOXAZOLE, PHTHALAZINE, XANTHONE, AND NAPHTHALEN-
2(1H)-ONE DERIVATIVES OF POTENTIAL PHARMACOLOGICAL
INTEREST
Chrysanthi Dolka,1 Virginia Dimaki,1 Petros G. Tsoungas,2 George Varvounis3
1Department of Chemistry, Section of Organic Chemistry and Biochemistry, University of Ioannina,
451 10 Ioannina, Greece; 2Department of Research and Technology, Ministry of Development,
14-18 Messogion Ave., Athens 115 10, Greece
Heterocycles are most prominently characterized as compounds of biological interest.1 Through the last
years anti-HIV research has been focused in molecules such as pyrrolyl(aryl or lindolyl)sulfones and
pyrrolylbenzothiadiazepines with reverse transcriptase inhibiting properties. 1,2-Benzisoxazoles have
been recently investigated as inhibitors of LTB4 binding to human neutrophiles, affinity ligands for
serotonergic and dopaminergic receptors, selective inhibitors of acetylcholinesterase or for atypical
antipsychotic activity. Our continuous interest in phthalazines focuses on their use in the synthesis of
semi-mimetics of angiotensin II and oxytocin inhibitors or DNA intercalators. Xanthone is a common
structure in Nature. Many of its derivatives bearing methyl, hydroxy, methoxy, or phenyl groups, or those
possessing complex polycyclic frameworks, have been isolated from 20 families of higher plants, fungi,
and lichens. It is also found in many natural products or other molecules exhibiting a broad spectrum of
pharmacological activity. Naphthalen-2(1H)-ones are an important class of pharmacologically active
compounds. 1-Hydroxy-1,6-dimethylnaphthalen-2(1H)-ones belong to a group of phytoalexines,
produced by the cotton plant Gossypium hirsutum when infected by bacteria. One member exhibits in
vitro chemotactic activity toward human polymorphonuclear leukocytes. Several non-natural compounds
are inhibitors of HIV-1 reverse transcriptase, genotype 1 hepatitis C virus (HCV) polymerase, and prolyl
hydroxylase activities.
In this lecture, the synthesis of novel pyrrole, indole, pyrrolobenzodiazepinedione, 1,2-benzisoxazole,
phthalazine, and naphthalene-2(1H)-ones derivatives will be described. Furthermore, the dimethyl ketal
of xanthone will be shown to undergo functionalization with a synthetically useful degree of
regioselectivity, using a lithiation protocol.
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IRON NANOMINERALIZATION IN AN AGED BLOOD PROTEIN:
IMPLICATIONS IN DISEASE BIOLOGY
Sandeep Verma
Department of Chemistry, IIT Kanpur, India
Life exists now in an oxidizing environment, and extracellular iron is largely present as Fe(III) rather than
Fe(II), as the former species are acidic and readily form hydroxo and oxo species in aqueous environment.
Iron biomineralization is a natural biological process: for example, iron is stored in ferritin as a form of
ferrihydrite, and magnetotactic bacteria use magnetite particles as navigational aids. On the other hand,
uncontrolled mineralization in biological systems can be deleterious and is thought to be involved in the
pathogenesis of various neurodegenerative diseases. We recently reported that human transferrin readily
forms protein fibrils and this aging process affords periodic iron nanomineralization along the length of
the fibrils.1 It is possible such processes may contribute to abnormal accumulation of iron in the brain,
which has been implicated a potential debilitating role in neurodegenerative diseases such as Parkinson’s,
Huntington’s, and Alzheimer’s. We will also elaborate recent results on this issue, which may unravel
molecular understanding of iron deposition leading to design of agents that disrupt human transferrin
aggregation.
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QSAR IN DRUG RESEARCH AND IN REGULATORY PROCESSES
Marjan Vracˇko
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Tel.: ?386-1-4760315, fax: ?386-1-4760300, e-mail: marjan.vracko@ki.si
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The QSAR paradigm grounds on assumption that the structure determines the biological properties of a
molecule. During the last decades, the QSAR faces strong development due the accessibility of chemical
information. The QSAR became well established in two areas: in drug research and in assessments of
properties used for regulatory purposes. The background mathematical technics and tools are basically the
same; however, the models developed for drug research and for regulatory purposes meet different
requirements.
In drug research, the QSAR is used for optimizing of structures respecting the bioactivity of a drug
candidate. In the first stage of drug discovery, it is used for searching of lead compounds where a large
quantity of data from high-throughput screening must be analyzed. In the later stage, the QSAR is used to
evaluate the ADME properties for (still) large number of candidates. Generally, in the searching of new
active compounds the fals positives are points of concern (synthesis and testing of a new fals positive is
expensive).
QSAR is used in regulatory processes for evaluation of physico-chemical, eco-toxicological, and
toxicological properties of chemicals. The models used for regulatory purposes should be developed in
spirit of OECD principles for validation of QSAR models, which ensure their transparency and
reproducibility. In the presentation, we discuss the role of QSAR methods in European Chemical
Legislation (REACH). Generally, for regulatory purposes usually the conservative evaluation of
predictions is considered (fals negatives are points of concern).
In the presentation, we present more details about strategies and methods in both areas and show some
examples. A discussion will be rised where both areas can interact.
AN EFFICIENT PRACTICAL SYNTHESIS OF THIO-BISPHOSPHONIC
ACIDS FOR THE TREATMENT OF ARTHRITIS, BASED ON THE
CHEMISTRY OF DISUFIDES
Wafaa M. Abdou, Abeer A. Shaddy
Chemical Industries Division, National Research Centre, Dokki, Cairo, Egypt. e-mail: wabdou@link.net
The bisphosphonates (BPs), in particular, the nitrogen containing analogs, have been demonstrated to be
potent inhibitors of bone resorption, and highly selective bone targeting agents. Lately, it has been
reported the utility of sulfur containing bisphosphonic acids (HSEDPR) in therapy of arthritis, particularly
rheumatoid. These results have led us to attempt to utilize the high bone/joint specificity of this class of
compounds together with other chemical moieties with potential anticatabolic pharmacology in the design
of specialized antiarthritic agents.







The S- and N-containing bisphosphonic acids have therefore examined as chondro-protective therapy
for the treatment of arthritis. Several of these have demonstrated potency both in vitro and in vivo. The
newly synthesized compounds all contain a latent or a free thiol group, which may bind to the zinc atom
in the active site of the matrix metalloproteases.
The most interesting series utilizes a rigid N-heterocycle group with a bisphosphonic acid as a
potential ‘‘bone hook’’ and a pendant thiol chain present for interaction with the enzyme systems. The
synthesis of these compounds was accomplished from the application of cyclic-, acyclic cis-disulfides,
and some arylidenes and halo-substrates. Hydrolysis of the resulting BPs affords the bisphosphonic acid.
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TARGETING THE HIV-1 TRANSCRIPTION COMPLEX: A CLINICAL
AND TRANSLATIONAL ENTERPRISE
Vanessa Pirrone,1,2 Shendra Passic,1,2 Jeffrey Jacobson,1,2,3 Sandhya Kortagere,1 Nirmala Rajagopalan,4
J. B. Suchitra,4 Zafar Khan,1,2 Michael R. Nonnemacher,1,2 Brian Wigdahl1,2
1Department of Microbiology & Immunology, 2Institute for Molecular Medicine & Infectious Disease,
3Division of Infectious Disease, HIV Medicine, Department of Medicine, Drexel University College of
Medicine, Philadelphia, PA, USA; 4Freedom Foundation, Bangalore, India
HIV-1 long terminal repeat (LTR) serves a number of critical functions in viral replication, one of the
most prominent of which involves regulating the transcriptional activity of the HIV-1 provirus. The HIV-
1 LTR (*630-660 bp) contains several cis-acting elements, which specifically bind host transcription
factors and thereby modulate promoter activity. We have previously demonstrated with clinical material
obtained in the pre-HAART era that sequence variation at HIV-1 LTR C/EBP site I and Sp site III, in
peripheral blood (PB)-derived LTRs, revealed sequence configurations that were found to increase in
prevalence with disease severity and correlate with HIV-associated dementia (HAD). In contrast, LTR
NF-jB sites I and II were highly conserved regardless of disease severity. Additional information has also
suggested that the viral trans-activator protein Tat and viral protein R (Vpr) may play integral roles in
regulating viral gene expression during the course of CNS disease and HIV disease in the peripheral blood
and lymphoid tissues based on highly specific interactions with sequences within and adjacent to the LTR
core/enhancer region as well as proteins involved in the basal, stimulated, and activated transcription
complex. To explore the impact of genetic variation within the HIV-1 subtype B LTR, Tat, and Vpr
sequences within the context of cross-population and longitudinal clinical studies in the era of
combination anti-retroviral therapy (ART), we have now enrolled more than 400 patients in the DREXEL
MEDICINE HIV/AIDS Genetic Analysis Cohort with approximately 1,100 remaining to be enrolled in this
continuously expanding clinical cohort. Utilizing a peripheral blood mononuclear cell (PBMC) PCR
product-based high throughput sequencing approach, we have identified a series single and co-selected
nucleotide polymorphisms (SNP and csSNP, respectively) in the viral LTR within 12 transcription factor-
binding sites that correlate with late stage HIV-1 disease. The SNP and csSNP identified based on their
increased prevalence in late-stage disease are being examined with respect to specific signatures in their
corresponding Env and Tat sequences. We are also exploring the functional properties of the HIV-1 LTR
and Tat protein with respect to genome activation in late stage HIV-1 disease. Studies are also underway
to explore the functional properties of the HIV-1 subtype C LTR and Tat protein regarding viral genome
activation.
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ANTIMICROBIAL ACTIVITY AND STRUCTURE–ACTIVITY
RELATIONSHIPS OF SOME SYNTHESIZED BENZAZOLES AND THEIR
POSSIBLE METABOLITES
Ismail Yalcin, Esin Aki, Ilkay Yildiz, Ozlem Temiz-Arpaci
Ankara University, Faculty of Pharmacy, Pharmaceutical Chemistry Department, Tandogan 06100,
Ankara, Turkey. e-mail: yalcin@ankara.edu.tr
The dramatically rising prevalence of multidrug-resistant microbial infections in the past few decades has
become a serious health care problem.1,2 In order to prevent this serious medical problem, the elaboration
of the new types of the previously known drugs is a very actual task.
Various fused heterocyclic compounds and different amides structures have been the aim of many
researches as an important class of antimicrobial agents for many years; because of they constitute
substantial chemotherapeutic activities. In the last few years, we reported some derivatives of benzazoles
such as benzoxazoles, benzimidazoles, benzothiazoles, and the possible metabolites of benzoxazoles
possessing amide structures, which are exhibited antibacterial and antifungal activities as well as showing
effects on some multidrug resistance strains.3,4
The antimicrobial activity results and the predictions for the lead optimization observed from the
QSAR analysis and common-features hypotheses that are generated by using Catalyst 4.9 for finding the
chemical features among the sets of synthesized fused heterocylic compounds and the possible
metabolites of benzoxazoles holding amide structures given in the figure below will be discussed.
X: -O-, -NH-, -S-   
Y : —, -CH2, -CH2-O-, -CH2-S- 
R : -H, -Me, -Cl, -NH2, -NO2, -COOMe, -NHCOCH2C6H5, -NHCOCH2C6H4Br,  
-NHCOCH2C6H4NO2, -NHCOCH2OC6H5
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